Metal-on-metal hip prostheses have been in use clinical since 1960s, and their safety and efficacy has never been reviewed adequately. The current reports of metal-on-metal hip implants’ failure have led to health concernsits. Literature review has been showing diverse changes. Clinical studies have been conducted to ascertain the usefulness of the technology in regard to its safety and efficacy. Ordinarily, metal-on-metal total hip implants are believed to release toxic substances in the patient’s body, causing significant health concerns of the technology.
Therefore, this paper will provide a critical review on the evidence for the safety and efficacy of metal-on-metal hip prostheses, primarily with regard to its insufficiency.
Table of Contents
Abstract
Introduction
Materials and Design
Clinical Safety and Efficacy
Conclusion
References
Research Objective and Topics
This paper provides a critical review of the safety and efficacy of metal-on-metal hip prostheses, specifically examining the insufficiency of the evidence provided by regulatory agencies prior to their widespread approval and usage.
- Historical context and clinical usage of metal-on-metal hip implants since the 1960s.
- Analysis of safety concerns, including the release of toxic metal ions and resultant peri-prosthetic tissue damage.
- Evaluation of regulatory oversight and the procedural failures in the FDA's approval process.
- Critique of technology assessment criteria regarding the lack of Randomized Clinical Trials (RCTs).
- Examination of the long-term health consequences for patients and the admission of device flaws by manufacturers.
Excerpt from the Book
Clinical Safety and Efficacy
Literature materials indicate that, FDA has not been able to design efficient regulatory measures aimed at reducing the risk posed by metal-on-metal hip arthroplasty. For instance, reports indicate that FDA was aware of the safety and efficacy issues related to metal-on-metal hip arthroplasty, but it maintained that there was a need for scientific data to unravel the mystery surrounding the technology. Surprisingly, FDA seems to have neglected the issue and continued to allow clearance of metal-on-metal hip implants for marketing. It is argued that FDA carries the blame for the damage incurred over the last thirty years for failing in its primary mission. In this case, the agency did not apply ethical standards in allowing clearance for metal-on-metal hip implants. It is argued that they were “fully aware of the deadly risks in use of toxic metal device failures for these implants, but the agency failed in its primary mission and continued to allow massive proliferation with full FDA clearance for marketing, unfettered by oversight” (Schrag 2013, p. 2).
Recently, Thomas P. Schmalzried astonished the public and healthcare professionals by testifying in the Chicago’s court case that he “had to revise 15 out of 66 insertions (23 percent failure rate), which he said, is an unacceptable failure rate” (Schrag 2013, p. 3). Ironically, FDA provided full market clearance for metal-on-metal hip implants in 2005, leading to the release of over 34,000 metal-on-metal devices in the United States. Schrag (2013, p. 3) reports “in a separate news report dated April 2, 2013, Dr. Schmalzried further testified that he would not use ASR and that its benefits do not outweigh the risk.” This testimony provides evidence to the safety and efficacy concerns on the metal-on-metal hip implants, but FDA seems to have neglected the risks associated with the implants for total hip replacement (Duncan et al. 2010).
Summary of Chapters
Abstract: Provides a high-level summary identifying that the technology assessment for metal-on-metal devices was based on inappropriate scientific evidence, leading to the conclusion of insufficient safety data.
Introduction: Outlines the historical usage of metal-on-metal prostheses and sets the stage for a critical review of the regulatory failures surrounding these devices.
Materials and Design: Details the specific systems analyzed in the study, such as the Cormet and Birmingham Hip Resurfacing systems, and identifies the use of the Cox regression model for data analysis.
Clinical Safety and Efficacy: Investigates the systemic failures of regulatory bodies and the clinical dangers, such as ion toxicity and tissue destruction, which were largely overlooked prior to device approval.
Conclusion: Reaffirms that the 2005 evidence for the safety and efficacy of these implants was insufficient and notes the problematic nature of the manufacturer-admitted device faults.
Keywords
Metal-on-metal hip prostheses, Hip arthroplasty, FDA, Technology assessment, Cobalt, Chromium, Regulatory failure, Clinical safety, Efficacy, Biomedical engineering, Implant failure, Toxic debris, Randomized clinical trials.
Frequently Asked Questions
What is the primary focus of this research paper?
The paper focuses on the critical review of the safety and efficacy of metal-on-metal hip prostheses, arguing that the evidence for their approval was insufficient.
What are the central themes discussed in the work?
Central themes include regulatory oversight failures, toxic metal ion release, long-term health risks to patients, and the inadequacies of the technology assessment process for new medical devices.
What is the ultimate goal or research question of this study?
The goal is to demonstrate that regulatory bodies, particularly the FDA, lacked sufficient, high-quality scientific evidence when granting market clearance for metal-on-metal hip implants in 2005.
Which scientific methodology is utilized in this paper?
The paper utilizes a literature review approach, analyzing existing data and reports through the lens of established technology assessment criteria and statistical modeling.
What topics are covered in the main body of the text?
The main body examines the history of the devices, the specific composition of the implants, clinical testimony regarding failure rates, and a comparative analysis of how the devices failed to meet required safety standards.
Which key terms best describe the work?
Keywords include hip arthroplasty, FDA regulatory failure, cobalt-chromium toxicity, and technology assessment.
What evidence is provided regarding the failure of these devices?
The author cites court testimonies from experts like Dr. Schmalzried, who reported unacceptable failure rates and adverse biological effects like peri-prosthetic tissue destruction.
Why does the author argue that the initial approval process was flawed?
The author argues the process was flawed because it relied on case studies rather than robust Randomized Clinical Trials (RCTs) and failed to satisfy the required technology assessment criteria for health outcomes.
- Quote paper
- Patrick Kimuyu (Author), 2017, The Evidence for the Safety and Efficacy of Metal-On-Metal Hip Prostheses, Munich, GRIN Verlag, https://www.hausarbeiten.de/document/381238
